Floatz logo

su011248

Clear Cell Renal Cell Carcinoma

PfizerPhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Clear Cell Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Girentuximab
Massachusetts General Hospital
Phase 3BB
gw786034
Academic and Community Cancer Research United
Phase 4BB
Bms-907351
SWOG Cancer Research Network
Phase 3BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB
Cyclophosphamide
City of Hope Medical Center
Phase 3B

View all 50 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →